Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
94 hedge funds and large institutions have $669M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 14 closing their positions.
1,251% more call options, than puts
Call options by funds: $21.4M | Put options by funds: $1.58M
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
84% more capital invested
Capital invested by funds: $365M → $669M (+$305M)
13% more funds holding
Funds holding: 83 → 94 (+11)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
10% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$11.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.63M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.49M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$4.48M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.31M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.73M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.63M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.49M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.34M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
SG Americas Securities
New York
| – | -$294K | -23,079 | Closed |
|
102
Parallax Volatility Advisers
San Francisco,
California
| – | -$28K | -2,184 | Closed |
|
103
US Bancorp
Minneapolis,
Minnesota
| – | -$18K | -1,458 | Closed |
|
|
DCM
104
Delpha Capital Management
New York
| – | -$11K | -824 | Closed |
|
105
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -600 | Closed |
|
|
RA
106
Royce & Associates
New York
| – | -$7K | -588 | Closed |
|
107
Group One Trading
Chicago,
Illinois
| – | -$12.6K | -568 | Closed |
|
JNCE Hedge Fund Activity: Q1 2018 in Review
94 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2018, worth a combined $669M — up 84% from $365M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new JNCE positions and 14 closed out — a net gain of 12 holders — while 26 added to existing stakes and 29 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $11.6M. The largest seller was Cormorant Asset Management, cutting an estimated $6.31M.
- 94 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2018, up from 83 in Q4 2017.
- Funds reported $669M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2018, up 84% quarter-over-quarter.
- 26 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2018 and 14 closed out, a net change of +12 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2018 was Avoro Capital Advisors, an estimated $11.6M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2018 was Cormorant Asset Management, an estimated $6.31M sold.
Based on aggregated 13F filings for Q1 2018.